The Association Between the Clinicopathological Characteristics and the Recurrence and Progression in Patients with Non-Muscle Invasive Bladder Cancer

Year 2015, Volume: 4 Issue: 3, 243 - 250, 01.09.2015

Gülzade Özyalvaçlı Mehmet Emin Özyalvaçlı Adnan Gücük Hesna Müzeyyen Astarcı Uğur Üyetürk Eray Kemahlı

https://doi.org/10.5505/abantmedj.2015.29052

Abstract

Objective: In this study our aim was to determine the association between the histopathological such as grade and stage and clinical parameters age, tumor size, the number of tumor and reTUR and prognosis in pTa and pT1 bladder carcinomas which diagnosed in Medical Faculty of Abant Izzet Baysal University AIBU . Method: In total 119 consecutive and newly diagnosed patients with pTa and pT1 bladder tumors were analyzed retrospectively between 2008 and 2013. The histopathological and clinical data were obtained from Pathology and Urology Department of AIBU. Results: There were 109 men and 10 women in this study. The average follow-up period was 30.14 months 2.86-80.74 . There was statistically significant difference between recurrence and tumor size, grade, stage, the number of tumors, re-TUR and smoking; as well as between progression and grade, tumor size, the number of tumors and smoking in univariate analyses. The independent predictive markers were tumor size OR: 5.26, %95CI: 1.42-19.55 and smoking OR: 4.65,%95CI: 1.23-17.53 in recurrence and only grade OR: 5.32,%95CI 1.37-20.59 in progression according to multivariate analyses. The estimated recurrence time was respectively 14,8 months 11.41-18.31 and 7,6 months 5.76-9.49 in the size of tumor

Keywords

Bladder cancer, grade, stage, recurrence, progression

Kas İnvaziv Olmayan Mesane Karsinomlu Hastalarda Klinikopatolojik Parametrelerin Rekürrens ve Progresyonla İlişkisi

Abstract

Amaç: Bu çalışmada Abant İzzet Baysal Üniversitesi AİBÜ Tıp Fakültesi’nde ilk tanısı pTa ve pT1 transisyonel hücreli mesane karsinomlu hastalarda evre ve grade gibi histopatolojik parametrelerin yanısıra yaş, tümör boyutu, tümör sayısı ve reTUR gibi klinik verilerin rekürrens ve progresyonla ilişkisinin ortaya konması amaçlanmıştır. Yöntem: 2008-2013 yılları arasındaki Abant İzzet Baysal Üniversitesi’nde ilk transüretral rezeksiyon TUR sonrası patolojik tanısı transizyonel hücreli mesane kanseri olarak rapor edilen pTa, pT1 ardışık 119 hasta retrospektif olarak değerlendirildi. Bu hastalara ait klinik veriler ve histopatolojik preparatlar AİBÜ Üroloji ve Patoloji A.D. arşivinden elde edildi. Bulgular: Çalışmamıza dahil edilen hastaların 109’u erkek, 10’u bayandı. Ortalama takip süresi 30.14ay 2.86-80.74 idi. Univariate analizinde rekürrens ile tümör boyutu, grade’i, evresi, sayısı, Re-TUR ve sigara kullanımı arasında istatistiki fark varken progresyon ile tümör grade’i, boyutu, sayısı ve sigara kullanımı arasında istatistiki fark vardı. Multivariate analizde rekürrensi belirlemede bağımsız prediktif faktörler tümör boyutu OR: 5.26,%95CI: 1.42-19.55 ve sigara kullanımı OR: 4.65,%95CI: 1.23- 17.53 iken progresyonu belirlemede sadece tümör grade’i saptandı OR: 5.32,%95CI 1.37-20.59 . Kaplan Meier analizinde tümör boyutu

Keywords

Mesane karsinomu, grade, evre, rekürrens, progresyon

References

• Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009 Jun;27(3):289-293.
• Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011 Aug 17;306(7):737-745.
• Mungan NA, Kiemeney LA, van Dijck JA, van der Poel HG, Witjes JA. Gender differences in stage distribution of bladder cancer. Urology. 2000 Mar;55(3):368-371.
• van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011 Sep;60(3):493-500.
• Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA. Prognosis of muscle- invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004 Mar;45(3):292-296.
• Shapur NK, Katz R, Pode D, Shapiro A, Yutkin V, Pizov G, et al. Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors. 2011 Apr 4;3(2):e22.
• Cheng L, Montironi R, Davidson DD, Lopez- Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 2009 Jun;22 Suppl 2:S70-95.
• Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stohr R, et al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol. 2014 Jan;65(1):218-226.
• Kilicli-Camur N, Kilicaslan I, Gulluoglu MG, Esen T, Uysal V. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int. 2002 Jul;52(7):463-469.
• Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466- 465; discussion 475-467.
• FK Mostofi: Histological typing of urinary tumors, In: Mostofi FK, Sobin LH, Torloni H (Eds): World Health Organization, 10th edition, Geneva 1973.
• Epstein JI: Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. In: Epstein JI, Eble JN, Sesterhenn I, Sauter G (Eds): World Health Organization Classification of Tumors. IARC Press, Lyon, France 2004:93
• Burger M, Denzinger S, Wieland WF, Stief CG, Hartmann A, Zaak D. Does the current World Health Organization classification predict the outcome better in patients with noninvasive bladder cancer of early or regular onset? BJU Int. 2008 Jul;102(2):194-197.
• Moyano Calvo JL, Romero Diaz A, Ortiz Gamiz A, Sanchez Sanchez E, Blanco Palenciano E, Arribas Rodriguez JM, et al. [The prognostic factors in T1 superficial bladder carcinoma. Our experience]. Arch Esp Urol. 1999 Jun;52(5):465-470.
• Portillo Martin JA, Val Bernal F, Garijo Ayenza F, Buelta Carrillo L, Martin Garcia B, Hernandez Rodriguez R, et al. [Prognostic factors in 243 transitional carcinomas of the bladder (II): microscopic parameters of the tumor and staging]. Arch Esp Urol. 1991 Mar;44(2):161-168.
• Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982 Feb;127(2):250- 252.
• Flamm J, Havelec L. Factors affecting survival in primary superficial bladder cancer. Eur Urol. 1990;17(2):113-118.
• Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, et al. Impact of smoking and smoking cessation on oncologic outcomes in primary non- muscle-invasive bladder cancer. Eur Urol. 2013 Apr;63(4):724-732.
• Lammers RJ, Witjes WP, Hendricksen K, Caris CT, Janzing-Pastors MH, Witjes JA. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol. 2011 Oct;60(4):713-720.
• Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive Dec;188(6):2120-2127. J Urol. 2012